Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4222624 | 0.98 | TSHR (0.47) | TSHRUSP2OPRM1OPRD1MAPT | |
| SCHEMBL8000862 | 0.92 | USP2 (0.48) | TSHRUSP2OPRM1OPRD1MAPT | |
| SCHEMBL4233198 | 0.89 | USP2 (0.56) | TSHRUSP2OPRM1OPRD1MAPT | |
| SCHEMBL2474112 | 0.89 | TSHR (0.53) | TSHROPRM1OPRD1MAPTHSD17B10 | |
| SCHEMBL4220744 | 0.89 | USP2 (0.53) | TSHRUSP2OPRM1OPRD1MAPT | |
| SCHEMBL2386705 | 0.88 | USP2 (0.58) | TSHRUSP2OPRM1OPRD1MAPT | |
| SCHEMBL8004767 | 0.88 | ALDH1A1 (0.49) | TSHRUSP2OPRM1OPRD1MAPT | |
| SCHEMBL4235024 | 0.87 | CASR (0.52) | TSHRUSP2OPRM1OPRD1MAPT | |
| SCHEMBL2385916 | 0.87 | USP2 (0.54) | TSHRUSP2OPRM1OPRD1MAPT | |
| SCHEMBL2384653 | 0.87 | MAPT (0.63) | TSHRUSP2OPRM1OPRD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012972-B2 | Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8012972-B2 | Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2133339-A1 | NOVEL (2-AMINOPHENYL)PYRIDINECARBOXAMIDE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2133339-A1 | NOVEL (2-AMINOPHENYL)PYRIDINECARBOXAMIDE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | HCAR1, CBR1, UACA | TSHR 167/4885USP2 1702/4885OPRM1 376/4885 |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | TSHR 4241/4885USP2 3063/4885OPRM1 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.